Mechanistic Assessment of Norepinephrine TheRapy vs. Angiotensin-II in Septic Shock (MANTRA) Grant Submission- Dysfunctional Renin-Angiotensin System in Septic Shock

Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.

开始日期2026-05-01

申办/合作机构

Wake Forest School of Medicine

[+1]

NCT07312292

/ Recruiting临床2期IIT

Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose

This clinical trial will test whether a short infusion of a drug called angiotensin II (AT-II) can make a liver cancer treatment work better. The drug is given directly into the artery that supplies blood to the liver, right before a treatment called yttrium-90 (90Y) radioembolization.
The main questions it aims to answer are:
* Does angiotensin II help more of the radioactive beads reach the tumor and less reach the healthy parts of the liver?
* Is it safe to add angiotensin II to the standard radioembolization treatment? What will participants do?
* First visit (work-up): Participants will have the standard preparation for radioembolization. A small test dose of radioactive tracer technetium 99mTc macroaggregated albumin (99mTc-MAA) will be injected into the liver through an artery. On the same day, a single-photon emission computed tomography (SPECT)/CT scan will be performed to see how the tracer distributes in the liver and if there are depositions outside the liver. If everything looks good, the participant will return for treatment in 2-3 weeks.
* Second visit (treatment): Participants will receive the actual radioembolization treatment. At each injection site in the liver, first angiotensin II is administered, immediately followed by the injection of the radioactive beads (90Y microspheres). If the treatment requires injections in multiple locations, the participant will receive angiotensin II at each spot.
* After treatment: Participants will receive a Positron Emission Tomography (PET)/CT scan so the research team can see where the radioactive beads went. This will be compared to the distribution of the radioactive tracer (99mTc-MAA) from the first SPECT/CT scan (performed without angiotensin II) to measure how much angiotensin II helped target the tumor.
All monitoring (including blood pressure, heart rate, oxygen saturation, and breathing rate) takes place during the procedure as part of routine care, and there are no extra hospital visits beyond what is normally required for radioembolization.

开始日期2026-01-01

申办/合作机构

Paion Deutschland GmbH

NCT07212686

/ Enrolling by invitation临床4期

An Open-Label, Single-Center Study of Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension Despite Receiving Fluid Therapy and Vasoactive Therapy

The goal of this clinical trial is to determine the safety and efficacy of Angiotensin-II in the treatment of pediatric patients in fluid refractory vasodilatory shock. The main questions it aims to answer are:
* To evaluate the change in blood pressure or reduction of vasoactive requirements (norepinephrine equivalent dosing) after initiating Angiotensin II
* To establish the safety and tolerability of Angiotensin-II in pediatric patients Participants will receive Angiotensin-II in addition to standard of care therapy for vasodilatory shock.
* The study team will then monitor the patient's vital signs, blood work, and for any potential side effects from the drug.
* An ultrasound will be performed to look at blood flow through the kidney in the setting of vasodilatory shock.
* A follow up phone call to check in with the patient will be performed 28 days after enrollment.

开始日期2025-09-09

申办/合作机构

Northwell Health, Inc.

[+1]

100 项与血管紧张素II 相关的临床结果

登录后查看更多信息

100 项与血管紧张素II 相关的转化医学

登录后查看更多信息

100 项与血管紧张素II 相关的专利（医药）

登录后查看更多信息

9,629

项与血管紧张素II 相关的文献（医药）

2026-08-01·BIOMATERIALS

Engineered extracellular vesicles from human placental mesenchymal stem cells attenuate abdominal aortic aneurysm formation by inhibiting Nat10-mediated vascular smooth muscle cell senescence

Article

作者: Fu, Ziwei ; Jia, Xiaoqian ; Bin, Jianping ; Hua, Yuhao ; Huang, Fuwen ; Hu, Xiao ; Fang, Qin ; Zeng, Jincai ; Zhang, Liwen ; Huang, Senlin ; Huang, Weichi ; Chen, Guojun ; Luo, Xiajing ; Wei, Guoquan ; Zheng, Hao

Human placental mesenchymal stem cell-derived extracellular vesicles (hPMSC-EVs) have demonstrated anti-senescence effects across various diseases. However, their role in abdominal aortic aneurysm (AAA), a degenerative aortic pathology, remains unexplored. Our findings demonstrated that hPMSC-EVs effectively delay vascular smooth muscle cell (VSMC) senescence. In vivo, modification of hPMSC-EVs with an osteopontin(OPN)-targeted peptide facilitated precise homing to aneurysmal sites and improved local retention. Additionally, administration of OPN-targeted hPMSC-EVs significantly reduced AAA formation in both AngII and elastase-induced murine models, by inhibiting VSMC senescence. Mechanistic studies further demonstrated that hPMSC-EVs suppressed VSMC senescence and lowered AAA incidence through downregulation of Nat10 expression. MiRNA sequencing identified miR-149-5p encapsulated in hPMSC-EVs as the key mediator of Nat10 suppression. These results position OPN-targeted hPMSC-EVs as a promising targeted therapy for AAA, exerting protective effects via the miR-149-5p/Nat10/senescence axis.

2026-03-01·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Osteopontin aggravates myocardial fibrosis by promoting phenotypic transition of cardiac fibroblasts via Hippo-YAP pathway

Article

作者: Chen, Sheng ; Liu, Chen ; Zeng, Guohua ; Huang, Qianqian ; Wang, Li ; Wang, Yuan ; Jiang, Chengzhi ; Huang, Qiren ; Liu, Wentao ; Xiong, Xiaowei

Osteopontin (OPN), a glycosylated protein ubiquitously in cellular matrix, exhibits a low expression in normal myocardial tissue but a high expression in fibrotic myocardial tissue. However, the action and mechanisms of OPN on the pathogenesis of myocardial fibrosis (MF) remain unclear. The purpose of the study is to investigate the action and mechanisms of OPN on the occurrence and development of MF, emphasizing abnormal activation of cardiac fibroblasts (CFs) and extracellular matrix (ECM) deposition. Both NIH-3T3 cells and C57BL/6 J mice were infected with OPN over-expression adenoviruses (Ad-Spp1). Cardiac function and fibrosis degree were evaluated in the presence and absence of angiotensin (AngII) (in vitro) or isoprenaline (ISO) (in vivo). Our data demonstrate that OPN over-expression results in myocardial injury and ECM accumulation under the physiological condition. Moreover, it exacerbates such effects under the pathological condition induced by AngII or ISO; in contrast, OPN knockdown attenuates the fibrotic response in vitro induced by AngII. Interestingly, OPN significantly promotes phenotypic conversion of CFs, characterized as elevated levels of α-SMA and Vimentin, with remarkable proliferation and migration in myocardial tissue. Mechanistically, our data indicate that such effects of OPN are mediated by nuclear translocation of YAP/TAZ via Hippo-YAP pathway, dependent of the membrane receptor integrin α_Vβ₃. Overall, OPN plays significant roles in the phenotypic transition of CFs via integrin-Hippo-YAP axis, ultimately leading to MF. The findings highlight the novel mechanisms of OPN triggering MF and would offer an early marker and potential targets for the prevention and treatment of MF.

2026-03-01·HYPERTENSION

Microbial Metabolite 4EPS Inhibits AT1R to Reduce Blood Pressure and Aortic Aneurysm Outcome

Article

作者: Karnik, Sadashiva S. ; Pardhi, Triveni R. ; Ravi, Tarun ; Naga Prasad, Sathyamangla V. ; Jara, Zaira Palomino ; Harford, Terri J. ; Singh, Khuraijam Dhanachandra ; Desnoyer, Russell ; Stenson, Kate ; Zalavadia, Ajay

BACKGROUND::

Plasma accumulation of the gut microbial metabolite 4-ethylphenylsulfate (4EPS), derived from dietary amino acid, tyrosine, has been associated with cardiovascular, renal, metabolic, and neurological disorders. AngII (angiotensin II) infusion increases circulating 4EPS in mice, suggesting a potential mechanistic role. We hypothesized that 4EPS modulates AngII-regulated pathophysiology and disease progression by directly inhibiting AT1R (angiotensin II type 1 receptor).

METHODS::

This hypothesis was tested by combining AT1R pharmacology, cell signaling assays, ex vivo vascular studies, an AngII-induced aortic aneurysm growth model, and plasma proteomics analysis.

RESULTS::

in vitro, 4EPS reduced the binding of both AngII and the antagonist candesartan to AT1R and suppressed AngII-induced calcium signaling. Ex vivo, 4EPS attenuated AngII-mediated vasoconstriction. In vivo, high-fat diet–fed ApoE-null mice coinfused with AngII and 4EPS showed significant blunting of blood pressure elevation and a marked reduction in aortic aneurysm–related mortality compared with mice infused with AngII alone. Analysis of aortic remodeling revealed increased elastin preservation and decreased thickening of the intimal and medial layers in 4EPS-treated animals. Plasma proteomics indicated alterations in actin–cytoskeletal signaling pathways consistent with reduced activation of ERK (extracellular-regulated kinase) 1/2, filamin-A, and proteins involved in vascular smooth muscle cell motility.

CONCLUSIONS::

These findings identify 4EPS as a benign, endogenous AT1R antagonist that diminishes AngII-mediated hemodynamic and vascular pathology. By suppressing cytoskeletal signaling associated with vascular remodeling, 4EPS provides significant protection against hypertension and aortic aneurysm progression in mice, revealing a previously unrecognized protective role for a gut microbial metabolite in modulating renin-angiotensin system activity.

167

项与血管紧张素II 相关的新闻（医药）

2026-04-02

·国际糖尿病idiabetes

ACC.26 | 面对降压的“天花板效应”，源头截流是否更有效？——KARDINAL Ⅱ期研究结果发布

点击“蓝字”关注我们编者按：在心血管医生的诊室里，最让人头疼的不是不吃药的患者，而是那些遵医嘱服药但血压依然岿然不动的患者。这种现象，我们称之为“难治性高血压”。难道人类的降压治疗真的存在一层无法逾越的“天花板”吗？近日，在2026年美国心脏病学会年会（ACC.26）上，Luke Laffin教授带来了关于新型降压药物Tonlamarsen的KARDINAL Ⅱ期研究最新结果，试图为我们揭开谜底。该研究成果同步发表在Journal of the American College of Cardiology。什么是降压“天花板效应”？——当人体启动了代偿机制所谓降压的“天花板效应”，是指在高血压治疗中，随着药物种类和剂量的不断增加，血压下降幅度却逐渐趋于平缓甚至停滞，同时副作用开始反扑。这背后的原因是人体的代偿机制：当用ACEI堵住了A通道，机体会选择绕过该通道，通过B途径（例如，非ACE途径产生的血管紧张素Ⅱ）或者通过反射性提高心率、增加钠水重吸收来维持血压。这种“你追我赶”的博弈，使得传统药物在进入多药联用阶段后，往往陷入了“加药不降压”的泥潭。治疗困境：难治性高血压引发的恶性循环目前难治性高血压的治疗面临巨大挑战，患者在长期降压治疗中，最隐性的代价是药物不断叠加所引发的副作用，以及由此导致的依从性下降所形成的恶性循环。多种药物叠加给患者带来的负担相当沉重，例如，利尿剂可能引发电解质紊乱，钙通道阻滞剂常导致下肢水肿，而多药联用还可能造成肾功能波动。这种治疗模式不仅增加了生理风险，也显著降低了患者的生活质量。更重要的是，这种复杂的用药方案对依从性提出了极高要求。每天需要精确服用四到五种药物的患者经常会有持续的紧张与不确定性，这也往往成为压垮依从性的最后一根稻草。从机制上看，肾素-血管紧张素-醛固酮（RAS）系统是人体血压调控的“中枢指挥系统”。目前主流的降压药物，如ACEI和ARB，主要作用于RAS系统的中下游环节。这类似于在河流中游筑坝：如果上游水源持续不断，下游的阻断终究存在被“溢流”的风险。因此，研究者逐渐将目光转向更上游的调控环节——由肝脏合成的血管紧张素原（AGT）。通过在源头减少底物供给，或许可以从根本上阻断RAS系统的过度激活，从而为难治性高血压提供一种全新的治疗路径。什么是AGT？揭秘血压调节的“源头活水” 如果把人体调节血压的RAS系统比作一条精密运行的“升压物质生产线”，那么AGT就是这条生产线上最源头、最基础的“原材料”。AGT主要由肝脏合成并释放到血液中，其本身并无升压作用，但通过以下两步“变形”后，演变成了血压的幕后推手：第一步（裁剪）：当血压下降时，肾脏会分泌一种叫“肾素”的酶。它像一把精准的剪刀，将血液中的AGT剪开，转化为血管紧张素Ⅰ。第二步（激活）：血管紧张素Ⅰ在转换酶的作用下，进一步蜕变为强大的血管紧张素Ⅱ。这才是导致血管剧烈收缩、血压飙升的“罪魁祸首”。 “源头截流”即可大力出奇迹？未必！ KARDINAL 研究提出了一种具有颠覆性的治疗假设：与其在RAS系统的下游反复“筑坝控流”，不如在源头直接“釜底抽薪”，从根本上减少升压信号的产生。基于这一思路，研究引入了一种创新性的反义寡核苷酸药物——Tonlamarsen。该药物能够选择性进入肝细胞，通过干扰AGT的基因表达，从源头抑制其合成过程，实现对RAS系统的上游调控。为了验证该假设，研究共纳入198例难治性高血压患者。所有入组患者在联合使用2～5种降压药物（其中超过80%已包含ACEI或ARB）的情况下，诊室收缩压仍高于135mmHg，提示常规治疗控制不佳。研究采用随机、双盲、安慰剂对照设计。所有患者在导入期均接受一次Tonlamarsen注射，随后按随机分配进入Tonlamarsen治疗组或安慰剂组，干预持续20周（见图1）。主要终点为评估干预前后血浆AGT水平及收缩压（SBP）的变化，以反映药物对 RAS 系统源头调控及降压效果的影响。次要终点包括安全性评估、动态血压监测结果，以及单次给药与多次给药方案之间疗效差异的比较。图1. KARDINAL 研究设计研究结果发现：与安慰剂组相比，Tonlamarsen治疗组的血浆AGT水平显著降低了67.2%（图2）。图2. Tonlamarsen治疗组与安慰剂组的血浆AGT水平变化两组的诊室收缩压（SBP）降幅无统计学上差异（图3）。图3. Tonlamarsen 治疗组与安慰剂组的诊室收缩压（SBP）变化安慰剂组的患者中（在导入期接受过一次Tonlamarsen单剂量给药），其AGT水平在20周后依然保持了约23%的残余抑制。在为期5个月的治疗过程中，Tonlamarsen表现出良好的安全性，未观察到严重的电解质紊乱或与药物相关的显著不良事件（表1）。表1. Tonlamarsen 治疗组与安慰剂组的不良事件发生率简而言之，KARDINAL试验证实：在已经联用多种药物的顽固性高血压患者中，Tonlamarsen可以有效地降低血浆AGT水平，但未显著降低患者的SBP。为何“源头截流”未能实现显著降压？尽管KARDINAL研究表明，Tonlamarsen在机制上实现了对AGT的显著抑制，但其降压效果并未呈现出预期效果。作者认为原因可能有以下几方面： 1.入组患者均为接受2~5种降压药的难治性高血压人群，ACEi/ARB等药物已阻断RAAS下游通路，大幅削弱了抑制上游AGT的潜在降压作用； 2：Tonlamarsen产生了意料之外的AGT持久抑制作用，导致安慰剂组在单次给药后20周仍存在残留降压效应，掩盖了治疗组多次给药的降压作用。 3：Tonlamarsen单次AGT抑制作用触发了机体的长期生理代偿，无需持续抑制即可维持降压效果，导致持续每月给药无法产生额外作用。 “意外收获”：从疗效强度到疗效持续性的转变尽管Tonlamarsen的降压效果并未突破难治性高血压的“天花板效应”，但研究也揭示了一个具有潜在变革意义的发现，即Tonlamarsen通过抑制AGT合成可能带来显著而持久的降压作用。研究显示，即便在停止给药后，Tonlamarsen对AGT的抑制作用仍可持续数月。这种“长效源头控制”的特性，为高血压治疗提供了新的可能路径——对于部分患者，未来或可通过“季度一次”甚至“半年一次”的给药方式，实现对血压的长期稳定控制，从而减少对每日口服多种药物的依赖。这一模式的转变，不仅有望改善治疗依从性，也可能在一定程度上重塑高血压的长期管理策略。小结： KARDINAL Ⅱ 期临床试验探索了从RAS系统上游抑制AGT合成对难治性高血压的治疗作用。尽管Tonlamarse实现了血浆AGT水平的显著降低且药物安全性良好，但未展现出显著的降压效果。然而，研究却发现该药物对AGT的抑制具有长效性，为高血压长效治疗、提升患者治疗依从性提供了新的探索方向。参考文献：1.Laffin LJ, et al. Efficacy of tonlamarsen in patients with uncontrolled hypertension: the KARDINAL phase 2 randomized clinical trial. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2026.03.0342.Efficacy and Safety of Tonlamarsen in Patients with Uncontrolled Hypertension.American College of Cardiology 2026, Scientific Sessions, Late-Breaking Clinical Trial. March 28, 2026 点击左下角“阅读原文”可查看文章原文声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《心肾代谢时讯》编辑部）

临床2期临床结果

2026-03-31

·今日头条

高血压疫苗深度科普：从“每天吃药”到“定期打针”的医学革命这不是预防针，而是利用免疫系统“精准拆弹”的慢性病管理新范式最近关于“高血压疫苗”的消息铺天盖地，很多人误以为打一针就能终身免疫。真相是：它并非预防你得高血压，而是一种“治疗性疫苗”。它的核心价值在于，有望将高血压治疗从“每天吃药”转

高血压疫苗深度科普：从“每天吃药”到“定期打针”的医学革命这不是预防针，而是利用免疫系统“精准拆弹”的慢性病管理新范式最近关于“高血压疫苗”的消息铺天盖地，很多人误以为打一针就能终身免疫。真相是：它并非预防你得高血压，而是一种“治疗性疫苗”。它的核心价值在于，有望将高血压治疗从“每天吃药”转变为“每1-2个月打一针”，彻底解决患者“漏服、忘服”的依从性难题。一、原理揭秘：免疫系统变身“降压药工厂” 传统降压药是外源性化学分子，代谢快，需每日服用。而高血压疫苗的原理是“教会”免疫系统自己生产降压药。 1. 精准靶向：以目前进展最快的国产疫苗 HJY-ATRQβ-001 为例，它靶向血管紧张素II 1型受体（AT1R）。简单说，就是诱导身体产生抗体，像“锁”一样锁住导致血压升高的“钥匙”（血管紧张素II），从而阻止血管收缩。 2. 长效机制：抗体在体内的半衰期远长于化学药。打一针后，抗体可维持1-3个月的有效浓度，实现长效平稳降压，尤其能有效控制清晨血压高峰（心梗高发时段）。 3. 安全性优势：相比早期靶向“肾素”的疫苗（曾引发肾脏损伤），新一代疫苗通过精细的表位筛选，避免了伤及无辜的自身免疫反应。二、全球进展：中国已领跑进入临床项目/团队靶点最新状态（2026年）关键特点 HJY-ATRQβ-001 （中国廖玉华团队） AT1R受体 I期临床（评估安全性）全球首个获批临床的治疗性降压疫苗，不激活RAS反馈，兼具靶器官保护 CYT006-AngQb （瑞士Cytos）血管紧张素II 曾完成IIa期证实了疫苗降压可行性，但疗效弱于现代药物，未上市 Zilebesiran （RNAi疗法）血管紧张素原 III期临床虽非疫苗，但同属长效生物制剂，半年打一针现状判断：虽然中国团队走在前列，但HJY-ATRQβ-001目前仅处于I期临床试验阶段，主要验证安全性和剂量。从I期到III期，再到最终获批上市，通常需要5-8年甚至更久。目前市面上没有任何一款正式上市的高血压疫苗，网传的“已上市”均为谣言。三、深度辨析：疫苗 vs 传统药物的利与弊优势（为什么值得期待） • 解决“依从性”痛点：中国高血压控制率仅约16.8%，主因是患者无法坚持每天服药。疫苗将治疗频次从每年365次降至6-12次，是革命性的突破。 • 平稳控压：抗体持续作用，避免了口服药“吃了降、不吃升”的血压波动，对保护心脑肾更有利。 • 副作用谱不同：可能规避某些化学药引起的咳嗽、脚踝水肿等副作用。局限与挑战（为什么不能神化） • 不是“一针永逸”：抗体滴度会随时间衰减，必须定期加强接种（如每2-3个月一次），绝非终身免疫。 • 无法替代生活方式：疫苗只解决“药”的问题，限盐、减重、运动依然是降压的基石，不能打了针就胡吃海喝。 • 个体差异大：免疫反应因人而异，未来可能需要根据抗体滴度进行个性化接种。 • 紧急情况难逆转：一旦发生严重低血压，抗体难以像口服药那样被快速清除或拮抗，这对急救提出了新挑战。四、专家建议与未来展望给患者的理性建议：在疫苗正式获批前，“规律服药（如ARB/ACEI/CCB）+ 健康生活”仍是金标准。切勿因等待疫苗而擅自停药，那将极大增加脑卒中、心衰的风险。未来趋势：高血压管理正走向“生物制剂时代”。未来可能是“疫苗 + siRNA + 口服药”的组合拳：用疫苗提供基础长效控制，用口服药进行微调，用siRNA（如Zilebesiran）针对特定难治性人群。总结：高血压疫苗是极具前景的“明日之星”，但它不是魔法。它让治疗更便捷，但无法根治疾病。科学理性看待，耐心等待临床数据的成熟，才是对健康负责的态度。

疫苗

2026-03-23

·研日新

研日新日报 ·2| 03月24日风湿免疫科 | 呼吸内科 | 重症医学科

日报精选医学文献今日精选20篇医学文献，查看更多请点击阅读原文本文支持继续浏览摘要内容；完整摘要、收藏文章、订阅管理等完整功能，请前往小程序「医研日新」。前往小程序查看更多与订阅收藏 1. Development of UM-200: A Novel Alkyne Amide-Based Inhibitor of the cGAS-STING Pathway. [Autoimmune Diseases] Journal of medicinal chemistry | 2026-03-23 | IF 6.0 AIUM-200通过优化弹头设计，在保持对多种STING变体活性的同时显著改善代谢稳定性，为STING相关炎症和自身免疫疾病提供了具有临床转化潜力的候选药物。摘要In response to double stranded DNA (dsDNA), the cGAS-STING pathway activates the innate immune response. While beneficial for detecting invading bacteria and viruses, overactivation of this pathway is associated with the development of several inflammatory and autoimmune diseases, making STING an attractive therapeutic target. Previously, we reported STING inhibitors that employ a nitrofuran warhe...查看完整摘要 2. Chinese recommendations for the diagnosis and management of non-radiographic axial spondyloarthritis. [Axial Spondyloarthritis] 综述 | Autoimmunity reviews | 2026-03-22 | IF 8.3 AI该建议为nr-axSpA提供了系统化的诊断标准和阶梯治疗方案，重点规范了影像学评估标准和生物制剂应用指征，有助于临床医师减少过度诊断并实现精准治疗。摘要The term of non-radiographic axial spondyloarthritis (nr-axSpA) has stimulated a number of practice-changing developments, but the meaning of nr-axSpA has not been well understood by clinicians, including rheumatologists. The diagnosis of nr-axSpA remains clinically problematic, with substantial risks of overdiagnosis. To generate a set of evidence-based recommendations for the diagnosis and manag...查看完整摘要 3. Ferroptosis inhibition and mitochondrial rescue: a novel mechanism of emodin in rheumatoid arthritis. [Arthritis] Redox report : communications in free radical research | 2026-03-22 | IF 5.2 AI大黄素可能通过靶向GPX4/ACSL4轴抑制铁死亡成为RA的辅助治疗新选择，为传统中药单体在自身免疫性疾病中的应用提供了现代药理学依据。摘要Rheumatoid arthritis (RA) is characterized by chronic synovitis and progressive joint destruction. Ferroptosis has been implicated in RA pathogenesis through synovial iron accumulation and oxidative stress. Glutathione peroxidase 4 (GPX4) and acyl-CoA synthetase long-chain family member 4 (ACSL4) are key regulators of ferroptosis, but their specific roles in RA remain incompletely defined. The obj...查看完整摘要 4. Evidence-based follow-up in axial spondyloarthritis: how much is (not) enough? [Axial Spondyloarthritis] Current opinion in rheumatology | 2026-03-17 | IF 5.2 AI患者主导随访和远程监测可安全减少稳定期轴型脊柱关节炎患者的门诊负担，优化医疗资源分配。摘要Present follow-up strategies for axial spondyloarthritis (axSpA) entail frequent preplanned in-person outpatient visits. Capacity constraints make this approach increasingly difficult, and it is plausible that regular follow-up in axSpA is not necessary for all patients. The purpose of this review is to discuss emerging alternative follow-up strategies to improve care efficiency in axSpA, and the ...查看完整摘要 5. Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy. [Autoimmune Diseases] 综述 | Cancer immunology, immunotherapy : CII | 2026-03-17 | IF 5.1 AI胸腺瘤患者接受免疫检查点抑制剂治疗时，中枢耐受缺陷导致高发严重免疫毒性，需优先评估自身免疫风险再制定治疗方案。摘要Thymic epithelial tumors (TETs) sit at a unique intersection of cancer, central tolerance, and autoimmunity. These tumors arise in the thymus, an immune-rich organ responsible for T-cell education, and despite their low tumor mutational burden (TMB) and microsatellite stability, they display paradoxical behavior under immune checkpoint inhibition. This review synthesizes data on thymic biology, pa...查看完整摘要 6. Transcriptomic analysis reveals lipid metabolism and macrophage involvement associated with nintedanib treatment in a rat bleomycin model. [Idiopathic Pulmonary Fibrosis] British journal of pharmacology | 2026-03-23 | IF 6.8 AI尼达尼布除经典抗纤维化机制外，还通过调控肺泡上皮-巨噬细胞脂质旁分泌轴发挥保护作用，为IPF治疗策略优化和联合用药开发提供新思路。摘要Idiopathic pulmonary fibrosis is a progressive lung disease with high clinical need. In this context, nintedanib significantly reduces acute exacerbation risk, however its comprehensive effect on fibrosis remains unclear. This study aims to evaluate nintedanib transcriptomic impact on lung fibrosis to uncover molecular signatures for new therapeutics. Lung fibrosis was induced by two intratracheal...查看完整摘要 7. Evaluation of Lung Disease in Adults with Osteogenesis Imperfecta: A Cross-Sectional, Multi-Center Study. [Bronchiectasis] Chest | 2026-03-22 | IF 9.5 AIOI患者肺部异常与脊柱侧弯程度无关，高分辨率CT应作为常规评估手段，提示疾病存在内在肺实质病变机制。摘要Osteogenesis imperfecta (OI) is a group of hereditary connective tissue disorders characterized by frequent fractures. Although cardiopulmonary impairment is a leading cause of mortality in the OI population, our understanding of the etiology of cardiopulmonary issues in OI remains limited. What are the cardiopulmonary outcomes and differences in pulmonary function in a cohort of 60 adults with OI...查看完整摘要 8. Fetal Exposure to Bisphenols and Phthalates and Risk of Respiratory Conditions in Infancy. The Generation R Next Study. [Asthma] Environmental research | 2026-03-22 | IF 7.7 AI临床应关注BPF、BPS及高分子量邻苯二甲酸酯的孕期暴露控制，这些物质可能增加婴儿哮喘症状反复发作风险。摘要Fetal exposure to bisphenols and phthalates may lead to alterations in the development of the respiratory and immune systems in children, subsequently increasing their susceptibility to respiratory conditions in infancy. We aimed to study the associations of fetal exposure to bisphenol and phthalate metabolites with the risk of respiratory conditions in infancy. This study, involving 1,295 mother-...查看完整摘要 9. Longitudinal Subphenotyping of Acute Respiratory Distress Syndrome: Implications in Prognostic Prediction and Clinical Intervention. [Pneumonia] Respirology (Carlton, Vic.) | 2026-03-22 | IF 6.6 AIARDS患者存在三种动态演变的亚表型，俯卧位通气对特定亚型有效，实时亚表型监测可指导精准干预。摘要To identify the longitudinal subphenotypes (LSPs) in patients with acute respiratory distress syndrome (ARDS) and their transitions, and to evaluate their potential for prognostic prediction and guiding interventions. This retrospective multicohort study derived its cohort from Zhongshan Hospital, Fudan University, China. Feature selection was performed using univariate analysis, recursive feature...查看完整摘要 10. Consensus palliative care referral criteria for people with idiopathic pulmonary fibrosis: An international Delphi study. [Idiopathic Pulmonary Fibrosis] Annals of the American Thoracic Society | 2026-03-22 | IF 5.4 AI该共识标准为IPF患者的姑息治疗转诊提供了循证依据，17项主要标准和40项次要标准可指导临床医生早期识别需要姑息介入的患者，改善患者生活质量。摘要People living with idiopathic pulmonary fibrosis (IPF) often experience rapid disease progression and high burden of distressing symptoms. Timely referral to specialist palliative care for people with IPF is uncommon. This study aims to establish consensus on criteria which would prompt a referral to specialist palliative care for people living with IPF. An international Delphi study was conducted...查看完整摘要 11. National Estimates of Pediatric Sepsis in US Hospitals Using Clinical Data. [Sepsis] JAMA | 2026-03-22 | IF 63.1 AI基于电子健康记录的脓毒症监测可替代行政编码，为临床医生提供更准确的实时预警，本研究证实的10%死亡率强调早期识别仍是改善预后的关键。摘要Pediatric sepsis causes substantial morbidity and mortality, but population surveillance relies on administrative codes with limited and variable accuracy. To estimate US national incidence, mortality, and trends of sepsis in nonneonatal children using a Pediatric Sepsis Event (PSE) definition adapted from the 2024 Phoenix criteria for scalable electronic health record (EHR)-based surveillance usi...查看完整摘要 12. Surveillance of Sepsis in Children-Making Every Case Count. [Sepsis] JAMA | 2026-03-22 | IF 63.1 AI建立标准化的儿童脓毒症监测体系是优化诊疗流程、改善患者预后的基础，建议各级医疗机构积极参与数据上报与质量改进项目。 13. Immediate or on demand necrosectomy for walled off necrosis: Two trials with different answers. [Pancreatitis] 社论 | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2026-03-22 | IF 11.6 AI对于包裹性坏死患者，手术时机的选择应根据感染程度、患者一般状况及囊肿包裹成熟度进行个体化决策，避免机械地采用立即或延迟任一策略。 14. Nano-sized DNase scavenges cell-free DNA for acute lung injury treatment. [Acute Lung Injury] Journal of controlled release : official journal of the Controlled Release Society | 2026-03-22 | IF 10.5 AIBRn@DNase I纳米系统通过双重机制（清除cf-DNA+抗氧化）同时抑制炎症和促进巨噬细胞向修复表型转换，为ALI提供了创新的精准治疗策略。摘要Excessive release of cell-free DNA (cf-DNA) from damaged cells activates DNA sensors, triggering robust inflammatory responses and contributing to the pathogenesis of acute lung injury (ALI). To address this, we developed a nano-sized DNase system by conjugating DNase I onto PEGylated bilirubin (BR) nanoparticles (BRn@DNase I) for efficient cf-DNA scavenging and inflammation resolution in ALI. Anc...查看完整摘要 15. Evaluating an asynchronous self-screening and patient-education tool for medication abortion without ultrasound. [Burns] American journal of obstetrics and gynecology | 2026-03-22 | IF 8.7 AI异步远程筛查工具可安全替代部分超声评估，为扩大药物流产可及性提供循证依据，尤其适用于基层及远程医疗场景。 16. Advances in retinal pigment epithelium transplantation for age-related macular degeneration: bridging biology to therapeutic frontiers. [Macular Degeneration] 综述 | Stem cell research & therapy | 2026-03-23 | IF 7.1 AIRPE移植技术正从实验走向临床，可能为难治性AMD患者提供视力保护甚至恢复的新希望，但细胞来源标准化和长期安全性仍是临床转化的核心瓶颈。 17. Preclinical efficacy and safety evaluation of human embryonic stem cell-derived functional hepatocytes for a clinical trial in acute liver failure. [Liver Diseases] Stem cell research & therapy | 2026-03-23 | IF 7.1 AIhESC衍生的肝细胞样细胞在临床前研究中展现出良好的安全性和显著疗效，为急性肝衰竭患者提供了一种潜在的新型细胞治疗方案。摘要Acute liver failure (ALF) is a life-threatening syndrome characterized by rapid deterioration of liver function, resulting in high mortality and posing a substantial global health burden. Human embryonic stem cells (hESCs) possess unlimited self-renewal capacity and pluripotent differentiation potential. Transplantation of hESC-derived hepatocyte-like cells (HPLCs) represents a promising therapeut...查看完整摘要 18. Efficacy of a Novel Dimeric Macrocyclic Gadolinium Chelate With High Relaxivity in Preclinical Models of Neurological and Oncological Pathologies. [Meningioma] Investigative radiology | 2026-03-23 | IF 7.0 AIDigadoglucitol作为首个二聚体大环GBCAs，半剂量即可达到现有对比剂的诊断效果，提示未来临床应用可能实现更低剂量、更高安全性的MRI对比增强方案。摘要Gadolinium-based contrast agents (GBCAs) are crucial for enhancing MRI contrast, especially in neurological and oncological imaging. Achieving high relaxivity is a primary focus in contrast media research. Recently, digadoglucitol, the first dimeric macrocyclic gadolinium complex, was introduced, offering significantly higher relaxivity compared with first-generation commercial macrocyclic GBCAs. ...查看完整摘要 19. Pharmacological inhibition of the interleukin-1 receptor-associated kinase prevents angiotensin II-induced cardiac remodelling in mice. [Heart Failure] British journal of pharmacology | 2026-03-23 | IF 6.8 AIIRAK-1/4抑制剂可作为心血管炎症性心力衰竭的潜在治疗策略，通过同时阻断炎症和纤维化两条关键通路发挥心脏保护作用。摘要Angiotensin II (AngII) induces cardiac hypertrophy but the exact mechanism is not known. The present study investigates the role of the interleukin-1 receptor-associated kinase (IRAK), in AngII-induced cardiac inflammation, fibrosis and hypertrophy. C57BL/6J male mice were infused with saline (sham) or AngII (1.5 mg·kg-1·day-1, subcutaneously) along with vehicle or IRAK-1/4 i...查看完整摘要 20. The role of stem cells and their engineering strategies in the repair of nerve damage in intracerebral hemorrhage. [Hemorrhage] 综述 | Cell & bioscience | 2026-03-23 | IF 6.1 AI工程化干细胞技术可能突破传统治疗瓶颈，为脑出血后神经功能恢复提供新的治疗策略。在小程序获取完整功能收藏文章、管理订阅、查看本期完整摘要与个性化内容，请前往小程序「医研日新」。前往小程序查看更多内容免责声明：仅供学术交流参考，不构成任何医学建议或诊疗指导

100 项与血管紧张素II 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	血管紧张素II	C01CX09	DB11842

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
分布性休克	欧盟	PAION AG	2019-08-23
分布性休克	冰岛	PAION AG	2019-08-23
分布性休克	列支敦士登	PAION AG	2019-08-23
分布性休克	挪威	PAION AG	2019-08-23
低血压	欧盟	PAION AG	2019-08-23
低血压	冰岛	PAION AG	2019-08-23
低血压	列支敦士登	PAION AG	2019-08-23
低血压	挪威	PAION AG	2019-08-23
脓毒性休克	欧盟	PAION AG	2019-08-23
脓毒性休克	冰岛	PAION AG	2019-08-23
脓毒性休克	列支敦士登	PAION AG	2019-08-23
脓毒性休克	挪威	PAION AG	2019-08-23
休克	美国	La Jolla Pharma LLC	2017-12-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝移植排斥反应	临床3期	美国	La Jolla Pharmaceutical Co.	2022-06-28
血管麻痹	临床3期	美国	La Jolla Pharmaceutical Co.	2022-06-28
脓毒症	临床3期	美国	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	澳大利亚	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	比利时	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	加拿大	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	芬兰	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	法国	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	德国	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	新西兰	La Jolla Pharmaceutical Co.	2015-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03733145 (CTgov)	临床4期	高血压 \| 低血压	32	Angiotensin II (Participants on ACE Inhibitors)	遞膚積簾簾鏇憲襯網鬱(構夢憲衊蓋鹽糧網廠鬱) = 夢構膚鏇鏇窪遞蓋範糧獵觸網糧構艱繭遞築範 (襯憲膚醖範鬱獵夢繭範, 衊壓淵願遞糧網鏇網獵 ~ 蓋築醖選壓廠鑰膚選襯) 更多	-	2025-08-24
				Angiotensin II (Participants on ARBs)	遞膚積簾簾鏇憲襯網鬱(構夢憲衊蓋鹽糧網廠鬱) = 襯衊顧鑰範鏇獵繭齋襯獵觸網糧構艱繭遞築範 (襯憲膚醖範鬱獵夢繭範, 夢簾鏇選構淵夢築範齋 ~ 獵網窪壓憲積蓋艱鹹範) 更多
NCT02338843 (ATHOS-3, Pubmed \| Crit Care)	临床3期	休克 baseline renin \| angiotensin-II \| renin/angiotensin-II ratio	-	Angiotensin-II	構獵醖鏇鏇選窪鏇醖艱(鏇淵鬱糧製淵齋鬱糧範) = 積獵鏇膚齋壓夢網製艱鏇範鏇廠製齋襯憲獵鑰 (艱夢顧蓋選蓋繭艱艱憲, 0.35 ~ 2.83)	积极	2025-02-19
				Placebo	構獵醖鏇鏇選窪鏇醖艱(鏇淵鬱糧製淵齋鬱糧範) = 鏇窪鬱鑰齋鏇鑰窪廠壓鏇範鏇廠製齋襯憲獵鑰 (艱夢顧蓋選蓋繭艱艱憲, -0.03 ~ 0.10) 更多
NCT04558359 (CTgov)	临床4期	急性肾损伤 \| 脓毒性休克	30	Standard of Care (Standard of Care Cohort)	顧鏇築鏇窪夢簾糧餘糧(淵積鹹觸鏇鬱顧鑰餘艱) = 築膚簾構簾蓋獵遞構鑰構窪艱糧淵製觸淵觸艱 (膚鑰夢艱觸壓願願齋窪, 鏇醖蓋觸襯網範築蓋網 ~ 選齋繭構衊鹽廠壓鹽網) 更多	-	2024-09-04
				Angiotensin II (Angiotensin II Cohort)	顧鏇築鏇窪夢簾糧餘糧(淵積鹹觸鏇鬱顧鑰餘艱) = 顧鏇鏇憲襯獵鹹膚鹽製構窪艱糧淵製觸淵觸艱 (膚鑰夢艱觸壓願願齋窪, 糧鹹齋齋繭願壓鬱糧餘 ~ 獵獵淵壓願築壓製餘鹹) 更多
ATS2024	N/A	成人呼吸窘迫综合征 \| 分布性休克	-	Angiotensin-II	網襯鹽蓋餘鬱選鑰製衊(餘範壓遞鏇憲網鹽醖範) = 積鹹憲選鏇襯鹽壓夢醖蓋積觸醖選夢窪鬱積餘 (鏇網憲鏇遞餘鹹膚壓淵, 160) 更多	-	2024-05-19
				Placebo	網襯鹽蓋餘鬱選鑰製衊(餘範壓遞鏇憲網鹽醖範) = 遞鹽夢選顧膚鬱繭築壓蓋積觸醖選夢窪鬱積餘 (鏇網憲鏇遞餘鹹膚壓淵, 74) 更多
ATS2024	N/A	肿瘤 \| 休克	40	Angiotensin II infusion	築醖餘觸壓廠構繭艱遞(鹹糧糧繭壓蓋遞繭齋餘) = a very low incidence of thrombotic events 鬱壓窪製鑰繭襯願製鏇 (築糧顧繭夢壓艱獵窪壓 )	积极	2024-05-19
NCT01393782 (ATHOS \| ATHOS trial, CTgov)	临床1期	脓毒性休克 \| 休克 \| 低血压	20	Angiotensin II (Angiotensin)	鏇蓋範製齋顧鑰鹹淵艱(製糧壓築鬱積鏇獵鏇遞) = 窪醖餘範齋願醖膚觸廠選齋願膚鬱鏇襯築繭醖 (簾鹽願積願鬱選窪廠遞, 12.4) 更多	-	2024-04-12
				Angiotensin II (Control)	鏇蓋範製齋顧鑰鹹淵艱(製糧壓築鬱積鏇獵鏇遞) = 窪糧繭構積願齋範齋鹽選齋願膚鬱鏇襯築繭醖 (簾鹽願積願鬱選窪廠遞, 29.3) 更多
ESC2024	N/A	休克	-	Angiotensin II	衊糧鑰鑰鬱壓遞築遞醖(積鑰觸蓋遞襯艱艱網夢) = 遞廠淵觸範鬱蓋觸夢艱淵網遞鬱築窪衊糧遞蓋 (醖製淵憲鏇窪艱鏇觸獵, 41 ~ 56) 更多	-	2024-03-08
NCT02338843 (ATHOS-3, Pubmed \| Ann Intensive Care)	临床3期	急性呼吸窘迫综合征 \| 休克	81	Angiotensin-II	繭醖襯構繭淵憲夢鹽鑰(憲築夢窪夢夢膚淵襯襯) = 簾襯獵鏇憲蓋衊繭醖壓艱鹽繭廠網鏇繭鑰鏇獵 (淵願選範繭襯襯鬱願築 ) 更多	积极	2023-12-16
				Placebo	繭醖襯構繭淵憲夢鹽鑰(憲築夢窪夢夢膚淵襯襯) = 願簾鏇淵膚願觸膚構糧艱鹽繭廠網鏇繭鑰鏇獵 (淵願選範繭襯襯鬱願築 ) 更多
NCT02338843 (ATHOS-3, Pubmed)	临床3期	休克	321	Angiotensin II	膚願築網鏇築膚願獵窪(築簾願遞餘顧簾餘窪觸): HR = 0.509 (95% CI, 0.274 ~ 0.945), P-Value = 0.03 更多	-	2023-05-05
				Placebo
NCT04529005 (CTgov)	临床4期	移植并发症 \| 休克 \| 分布性休克 ... 更多	20	Angiotensin II	窪衊鹹製廠齋鹽艱窪蓋(鬱選廠衊築糧鑰鹹憲顧) = 窪鑰觸壓構製範遞鑰網餘窪糧齋鏇範範簾鏇鏇 (廠襯遞鹽簾鑰糧糧顧餘, 鹹蓋鹹築鏇簾遞觸繭鹹 ~ 餘襯繭積蓋窪蓋膚衊遞) 更多	-	2022-12-21